Search results
Results from the WOW.Com Content Network
ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. [ 2 ] [ 5 ] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
Immunogen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine fails to meet primary endpoint in a phase III monotherapy study. Shares of the company decline almost 47%.
The mirvetuximab, which has been submitted for FDA approval, is being developed as a monotherapy or a standalone treatment for ovarian cancer. [7] [8] Other products currently in clinical-stage development include: [9] IMGN853, (mirvetuximab soravtansine) targeting FRα, and using DM4. [10] IMGN529, targeting CD37 for Non-Hodgkin lymphoma (NHL ...
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.
For premium support please call: 800-290-4726 more ways to reach us
Silmitasertib (), codenamed CX-4945, is a small-molecule inhibitor of protein kinase CK2 (casein kinase II), a constitutively active serine/threonine-specific protein kinase that is overexpressed in several types of tumors.